

REVIEW

Open Access



Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments

Saife N. Lone^{1†}, Sabah Nisar^{2†}, Tariq Masoodi², Mayank Singh³, Arshi Rizwan⁴, Sheema Hashem², Wael El-Rifai^{5,6,7}, Davide Bedognetti^{8,9,10}, Surinder K. Batra^{11,12,13}, Mohammad Haris^{2,14,15}, Ajaz A. Bhat^{2*} and Muzafar A. Macha^{16*}

Abstract

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. Liquid biopsies consist of isolating tumor-derived entities like circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc., present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them. Methods for isolation and analysis of liquid biopsies have rapidly evolved over the past few years as described in the review, thus providing greater details about tumor characteristics such as tumor progression, tumor staging, heterogeneity, gene mutations, and clonal evolution, etc. Liquid biopsies from cancer patients have opened up newer avenues in detection and continuous monitoring, treatment based on precision medicine, and screening of markers for therapeutic resistance. Though the technology of liquid biopsies is still evolving, its non-invasive nature promises to open new eras in clinical oncology. The purpose of this review is to provide an overview of the current methodologies involved in liquid biopsies and their application in isolating tumor markers for detection, prognosis, and monitoring cancer treatment outcomes.

Keywords: Liquid biopsy, Cancer, Circulating tumor cells, Circulating tumor DNA, Tumor extracellular vesicles, Non-invasive tumor detection, Precision medicine Cancer diagnosis

Introduction

Molecular profiling of tumors obtained from individual patients has in recent years been shown to improve

the selection of personalized cancer treatment therapies, patient responses, detection of drug resistance, and monitoring of tumor relapse [1, 2]. The standard method of profiling tumors initially involves obtaining resected tumor samples by invasive surgeries. The limitations to such invasive procedures include difficulty in acquiring tumor samples for both tumor quantity and quality (Fig. 1). Moreover, acquiring biopsy samples by invasive methods throughout treatment to monitor tumor response and relapse also poses a major challenge in tumor profiling [3]. Heterogeneity of resected tumor samples as a whole, also limits the use of invasive

*Correspondence: abhat@sidra.org; muzafar.macha@islamicuniversity.edu.in; muzafar.aiiims@gmail.com

[†]Saife N. Lone and Sabah Nisar contributed equally to this work.

²Laboratory of Molecular and Metabolic Imaging, Cancer Research Department, Sidra Medicine, PO BOX 26999, Doha, Qatar

¹⁶Watson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, (IUST), 192122 Awantipora, Jammu & Kashmir, India

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.